LRIG and cancer prognosis.
LRIG and cancer prognosis.
复制标题
DOI：
10.3109/0284186x.2014.953258
复制
发表时间：
2014-09
期刊：
影响因子：
--
通讯作者：
Hedman H
中科院分区：
文献类型：
--
作者：
Lindquist D;Kvarnbrink S;Henriksson R;Hedman H
癌症患者的最佳治疗决策需要可靠的预后和预测信息。然而，在许多情况下，这一信息并不充分。最近的几项研究表明，富含亮氨酸的重复序列和免疫球蛋白样结构域（LRIG）基因，转录本和蛋白质在各种癌症类型中具有预后意义。使用关键词lrig 1、lrig 2和lrig 3在PubMed上识别相关文献。使用Oncomine数据库研究癌症与正常组织中的LRIG mRNA表达。三种人LRIG基因，LRIG 1、LRIG 2和LRIG 3，编码单程跨膜蛋白。LRIG 1是生长因子信号传导的负调节剂，其已被证明在体外和小鼠体内起肿瘤抑制剂的作用。LRIG 2和LRIG 3的功能不太明确。LRIG基因和蛋白质表达通常在人类癌症中失调。在早期乳腺癌中，LRIG 1拷贝数最近被证明可以预测早期和晚期复发以及总生存率;在鼻咽癌中，LRIG 1的丢失也与生存率低相关。LRIG基因和蛋白表达在乳腺癌、宫颈癌、头颈癌、胶质瘤、非小细胞肺癌、前列腺癌和皮肤鳞状细胞癌中具有预后价值。一般来说，LRIG 1和LRIG 3的表达与良好的存活相关，而LRIG 2的表达与较差的存活相关。此外，LRIG 1调节细胞对抗癌药物的敏感性，这表明可能作为预测标记物发挥作用。LRIG基因状态以及mRNA和蛋白质表达是几种类型的人类癌症的临床相关预后指标。我们建议，LRIG分析可能成为重要的知情和个性化的临床决策时，对癌症患者的管理。
Optimal treatment decisions for cancer patients require reliable prognostic and predictive information. However, this information is inadequate in many cases. Several recent studies suggest that the leucine-rich repeats and immunoglobulin-like domains (LRIG) genes, transcripts, and proteins have prognostic implications in various cancer types. Relevant literature was identified on PubMed using the key words lrig1, lrig2, and lrig3. LRIG mRNA expression in cancer versus normal tissues was investigated using the Oncomine database. The three human LRIG genes, LRIG1, LRIG2, and LRIG3, encode single-pass transmembrane proteins. LRIG1 is a negative regulator of growth factor signaling that has been shown to function as a tumor suppressor in vitro and in vivo in mice. The functions of LRIG2 and LRIG3 are less well defined. LRIG gene and protein expression are commonly dysregulated in human cancer. In early stage breast cancer, LRIG1 copy number was recently shown to predict early and late relapse in addition to overall survival; in nasopharyngeal carcinoma, loss of LRIG1 is also associated with poor survival. LRIG gene and protein expression have prognostic value in breast cancer, uterine cervical cancer, head-and-neck cancer, glioma, non-small cell lung cancer, prostate cancer, and cutaneous squamous cell carcinoma. In general, expression of LRIG1 and LRIG3 is associated with good survival, whereas expression of LRIG2 is associated with poor survival. Additionally, LRIG1 regulates cellular sensitivity to anti-cancer drugs, which indicates a possible role as a predictive marker. LRIG gene statuses and mRNA and protein expression are clinically relevant prognostic indicators in several types of human cancer. We propose that LRIG analyses could become important when making informed and individualized clinical decisions regarding the management of cancer patients.